- Pre-existing Immunocompromised Status as a Preventer of Mortality in COVID-19 Patients: Friend or Foe? Cureus
- RECOVERY trial finds that empagliflozin is not an effective treatment for patients hospitalised with COVID-19 — RECOVERY Trial RECOVERY Trial
- View Full coverage on Google News
from Health - Latest - Google News
0 comments:
Post a Comment